Shana Kelley is a Professor within the Leslie Dan Faculty of Pharmacy (Pharmaceutical Sciences), and Faculty of Medicine (Biochemistry) at the University of Toronto. She is also a member of the Institute of Biomaterials and Biomedical Engineering and cross-appointed to the Department of Chemistry. She is an expert in the development of new nanomaterials for biological and cellular sensing, and the development of drug delivery systems - two areas of significant importance for the development of new medical technologies. Shana is a highly interdisciplinary scientist who uses her foundation in Chemistry to develop solutions for interesting biological problems, and excels at weaving together the necessary elements from this field and materials science, nanoengineering and molecular biology to produce novel systems with high levels of performance. To enrich her research approach further and increase its impact, she collaborates extensively with electrical engineers, mechanical engineers, oncologists, and infectious disease specialists.
Dr. Kelley obtained her Ph.D. at the California Institute of Technology in Chemistry in 1999 and her B.A. summa cum laude from Seton Hall University in 1994. She began her independent career in 2000 at Boston College, was promoted directly to Full Professor in 2006, and moved that same year to University of Toronto as a Full Professor. Her publications have been cited over 4500 times, with 11 papers cited over 100 times and over 48 papers cited over 20 times.
Dr. Kelley's laboratory is funded by a variety of provincial and federal sources both from Canada and the United States. NSERC, CIHR, OCE, OICR, the Prostate Cancer Research Foundation, Genome Canada, the U.S. NIH, U.S. DoD and ORF have all backed her research efforts. Shana's 18 member research team currently includes graduate students, postdoctoral fellows, undergraduate students and technical staff. Previous members of her group have gone on to pursue prestigious positions at institutions including MIT, Harvard, McGill, and Stanford. She has also placed her graduates at some of the best pharmaceutical and biotech companies in the world, including Millenium, Vertex, Applied Biosystems and Pfizer. Her graduates are also pursued aggressively by start-up biotech and medical diagnostic companies, as the interdisciplinary training they receive is ideal preparation for the dynamic environment offered by early stage companies.
Dr. Kelley has been recognized for her contributions with several awards. She was named one of "Canada's Top 40 under 40" in 2008. In 2009, she received a highly prestigious NSERC E.W.R. Steacie Fellowship. In 2011 she was named a University of Toronto "Inventor of the Year" and also won the Steacie Prize. She has also been recognized with the Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a Dreyfus New Faculty Award, and was also named a "Top 100 Innovator" by MIT's Technology Review.